Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 1606-85-5 | MDL No. : | MFCD00002883 |
Formula : | C8H14O4 | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | IXAWTPMDMPUGLV-UHFFFAOYSA-N |
M.W : | 174.19 | Pubchem ID : | 62411 |
Synonyms : |
|
Num. heavy atoms : | 12 |
Num. arom. heavy atoms : | 0 |
Fraction Csp3 : | 0.75 |
Num. rotatable bonds : | 6 |
Num. H-bond acceptors : | 4.0 |
Num. H-bond donors : | 2.0 |
Molar Refractivity : | 43.23 |
TPSA : | 58.92 Ų |
GI absorption : | High |
BBB permeant : | No |
P-gp substrate : | No |
CYP1A2 inhibitor : | No |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -8.34 cm/s |
Log Po/w (iLOGP) : | 1.95 |
Log Po/w (XLOGP3) : | -1.38 |
Log Po/w (WLOGP) : | -0.91 |
Log Po/w (MLOGP) : | -0.58 |
Log Po/w (SILICOS-IT) : | 0.54 |
Consensus Log Po/w : | -0.08 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 1.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | 0.35 |
Solubility : | 386.0 mg/ml ; 2.22 mol/l |
Class : | Highly soluble |
Log S (Ali) : | 0.64 |
Solubility : | 767.0 mg/ml ; 4.4 mol/l |
Class : | Highly soluble |
Log S (SILICOS-IT) : | -0.72 |
Solubility : | 33.3 mg/ml ; 0.191 mol/l |
Class : | Soluble |
PAINS : | 0.0 alert |
Brenk : | 1.0 alert |
Leadlikeness : | 1.0 |
Synthetic accessibility : | 3.46 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P280-P305+P351+P338 | UN#: | N/A |
Hazard Statements: | H302 | Packing Group: | N/A |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
24% | With I2; Ki; In water; | Example 6 2,2'-[2,3-diiodo-2-butene-1,4-diylbis(oxy)]-bis-ethanol (9) <strong>[1606-85-5]1,4-bis-(2-hydroxyethoxy)-2-butyne</strong> (8 , 87.12 g, 0.50 mol) was added to a solution of KI (172.04 g, 1.04 mol) and I2(129.51 g, 0.51 mol) in water (1500 ml). The reaction mixture was heated under reflux for 3 hours and stirred at room temperature over night. The lower brown-black organic phase was separated and the aqueous phase was extracted with diethyl ether. The combined organic phases were evaporated and gave 289 g crude product. 7 g of the crude product were purified by preparative HPLC (RP-18 column with H2O:CH3CN = 8:2). This gave 1.7 g of 9 as a slight yellow cotton like solid in 24 % yield. MP. 79-82C. TLC on silica; EtAc:CH3CN = 1:1, Rf= 0.52. Aqueous solubility at 20C = 7.2 g/L. |
[ 944561-44-8 ]
2-[2-(2-Propynyloxy)ethoxy]ethylamine
Similarity: 0.65
[ 762-21-0 ]
Diethyl acetylenedicarboxylate
Similarity: 0.56
[ 944561-44-8 ]
2-[2-(2-Propynyloxy)ethoxy]ethylamine
Similarity: 0.65
[ 143-24-8 ]
2,5,8,11,14-Pentaoxapentadecane
Similarity: 0.60
[ 112-27-6 ]
2,2'-(Ethane-1,2-diylbis(oxy))diethanol
Similarity: 0.60
[ 2615-15-8 ]
3,6,9,12,15-Pentaoxaheptadecane-1,17-diol
Similarity: 0.60
[ 944561-44-8 ]
2-[2-(2-Propynyloxy)ethoxy]ethylamine
Similarity: 0.65
[ 143-24-8 ]
2,5,8,11,14-Pentaoxapentadecane
Similarity: 0.60
[ 112-27-6 ]
2,2'-(Ethane-1,2-diylbis(oxy))diethanol
Similarity: 0.60
[ 2615-15-8 ]
3,6,9,12,15-Pentaoxaheptadecane-1,17-diol
Similarity: 0.60
[ 112-27-6 ]
2,2'-(Ethane-1,2-diylbis(oxy))diethanol
Similarity: 0.60
[ 2615-15-8 ]
3,6,9,12,15-Pentaoxaheptadecane-1,17-diol
Similarity: 0.60
[ 23783-42-8 ]
2,5,8,11-Tetraoxatridecan-13-ol
Similarity: 0.60
[ 5617-32-3 ]
3,6,9,12,15,18-Hexaoxaicosane-1,20-diol
Similarity: 0.60